Previse Raised $3M in Seed Round
Previse, formerly known as Capsulomics, Inc., announced the closing of a $3 million seed round and the launch of its first laboratory-developed test, EsopredictTM. With a five-year survival rate of 20% after diagnosis, esophageal cancer is one of the most lethal cancers in the world. According to the American Cancer Society, approximately 21,560 new cases of … Read more